Kimberly Blackwell - 01 Feb 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: Chief Executive Officer, Director
Signature: By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kimberly Blackwell
Issuer symbol: ZNTL
Transactions as of: 01 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 01 Feb 2023, 18:08:10 UTC
Previous filing: 16 Jun 2022
Next filing: 15 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Award	$0	+244,800	+4896%	$0.000000	249,800	01 Feb 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option (Right to Buy)	Award	$0	+355,200		$0.000000	355,200	01 Feb 2023	Common Stock	355,200	$23.65	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2	The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.